Tonix Pharmaceuticals

Yahoo Finance • 17 days ago

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

CHATHAM, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated commercial-stage biotechnology company today announced the appointment of Irina Ishak as G... Full story

Yahoo Finance • 22 days ago

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations

AUSTIN, Texas, Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with the National Insti... Full story

Yahoo Finance • last month

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026 More than 21 million US adults experience a major depressive episode each year CHATHAM, N.J., Nov. 24, 20... Full story

Yahoo Finance • last month

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment

TONMYA is now available by prescription and available for pharmacy ordering nationwide TONMYA is the first FDA-approved treatment for fibromyalgia in more than 15 years TONMYA is a unique, non-opioid, once-daily bedtime analgesic that si... Full story

Yahoo Finance • last month

Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia set to launch in November Tonmya is the first new FDA-approved medicine for fibromyalgia in more than 15 years Cash and cash equivalents of $190.1 million... Full story

Yahoo Finance • 2 months ago

Tonix Pharmaceuticals Holding Corp (TNXP) Showcases Promising TNX-801 Vaccine Data

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) is one of the top long-term biotechnology stocks to buy. On October 17, Tonix Pharmaceuticals (NASDAQ:TNXP) presented encouraging preclinical data for its investigational mpox and smallpox v... Full story

Yahoo Finance • 2 months ago

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Treatment was well tolerated with minimal effects on weight or blood pressure and discontinuation rate of 19% vs. placeb... Full story

Yahoo Finance • 2 months ago

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix’s investigational intranasal potentiated oxytocin products in patients with Arginine-Vasopressin Deficiency (AVP-D) The trial is intended to... Full story

Yahoo Finance • 2 months ago

Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

TNX-801 is a live virus vaccine investigational candidate, designed to provide durable protection against mpox and smallpox TNX-801 demonstrated favorable safety, immunogenicity, and long-term protection in multiple preclinical models Da... Full story

Yahoo Finance • 3 months ago

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

CHATHAM, N.J., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, tod... Full story

Yahoo Finance • 3 months ago

Tonix to advance cyclobenzaprine into phase 2 for depression

[Depressed woman. Sadness and headache concept] simpson33 * Tonix Pharmaceuticals (NASDAQ:TNXP [https://seekingalpha.com/symbol/TNXP]) said that it will advance cyclobenzaprine, currently marketed under the brand name Tonmya as a sublin... Full story

Yahoo Finance • 3 months ago

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access

Mr. Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix On August 15, 2025, the U.S. Food and Drug Administration approved Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the trea... Full story

Yahoo Finance • 3 months ago

Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026

Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND TNX-2900 granted Orphan Drug and Rare Pediatric Dise... Full story

Yahoo Finance • 3 months ago

Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

Tonix anticipates filing the IND application in the fourth quarter of 2025 TNX-102 SL is a potential first-in-class treatment for targeting the disturbed sleep associated with depression TNX-102 SL is FDA-approved for the treatment of fi... Full story

Yahoo Finance • 3 months ago

Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: 1) Planning adaptive Phase 2/3 study Approximately 70 million people that are eligible for treatment live in a... Full story

Yahoo Finance • 4 months ago

Mpox in Africa is no longer a global health emergency, WHO chief says

[Blood collection tubes Mpox test positive results,WHO to rename monkeypox as ‘Mpox’] JUN LI The mpox outbreak that originated from Africa last year can no longer be considered a global emergency due to a sustained decline in cases and im... Full story

Yahoo Finance • 4 months ago

SA analyst upgrades/downgrades: HD, AAPL, TMUS, TNXP

[Stock market and exchange concept with skyline, bar graph, chart and stock ticker.] Torsten Asmus Home Depot (HD [https://seekingalpha.com/symbol/HD]) sees a downgrade due to overvaluation concerns amidst mixed financial results, while T... Full story

Yahoo Finance • 4 months ago

Tonix wins FDA approval of fibromyalgia drug Tonmya

[Neurological diagnosis of Fibromyalgia. Neurological hammer, human brain figure, tools for sensitivity testing are on table next to title of text diagnosis of Fibromyalgia in workplace of neurologist] Shidlovski/iStock via Getty Images... Full story

Yahoo Finance • 4 months ago

Tonix Pharmaceuticals stock halted ahead of FDA approval news

Investing.com -- Trading was halted in Tonix Pharmaceuticals (NASDAQ:TNXP) stock Friday ahead of a major announcement that the U.S. Food and Drug Administration (FDA) has approved Tonmya for the treatment of fibromyalgia in adults. The ap... Full story

Yahoo Finance • 4 months ago

FDA approves Tonix's fibromyalgia treatment, first in 15 years

CHATHAM, N.J. - Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced Friday that the U.S. Food and Drug Administration has approved Tonmya (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, marking... Full story